Lilly is the co-founder and CEO of Synteny, a startup harnessing the adaptive immune system and artificial intelligence to engineer a
new generation of diagnostics, therapeutics and vaccines . Previously, Lilly was co-head of the Growth Equity platform for
Generation Investment Management, where she was responsible for the firm’s investments in sustainable technology companies (climate change and healthcare solutions).
After a 20-year track record in finance and investing, Lilly pursued a graduate degree in Computational Biology from the University of Cambridge and was awarded the MPhil in Computational Biology (with distinction) in the fall of 2021. At Cambridge, she worked as a research intern in the CRUK Early Detection Programme and completed her masters thesis focused on generative models of TCR repertoires as part of the Accelerate Programme for Scientific Discovery.
Lilly Wollman's papers